Nanomaterials, Autophagy, and Lupus Disease

被引:9
作者
Bianco, Alberto [1 ]
Muller, Sylviane [1 ,2 ]
机构
[1] CNRS, Immunopathol & Chim Therapeut, Inst Biol Mol & Cellulaire, UPR3572, 15 Rue Rene Descartes, F-67000 Strasbourg, France
[2] Univ Strasbourg, Inst Adv Study, 5 Allee Gen Rouvillois, F-67083 Strasbourg, France
关键词
autoimmune diseases; autophagy; inflammation; lupus; nanostructures; COMPLEMENTARITY-DETERMINING REGION-1; FUNCTIONALIZED CARBON NANOTUBES; CHAPERONE-MEDIATED AUTOPHAGY; T-CELLS; AUTOIMMUNE-DISEASES; THERAPEUTIC TARGET; PEPTIDE; ERYTHEMATOSUS; AUTOANTIBODIES; MODULATION;
D O I
10.1002/cmdc.201500233
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Nanoscale materials hold great promise in the therapeutic field. In particular, as carriers or vectors, they help bioactive molecules reach their primary targets. Furthermore, by themselves, certain nanomaterials-regarded as protective-can modulate particular metabolic pathways that are deregulated in pathological situations. They can also synergistically improve the effects of a payload drug. These properties are the basis of their appeal. However, nanoscale materials can also have intrinsic properties that limit their use, and this is the case for certain types of nanomaterials that influence autophagy. This property can be beneficial in some pathological settings, but in others, if the autophagic flux is already accelerated, it can be deleterious. This is notably the case for systemic lupus erythematosus (SLE) and other chronic inflammatory diseases, including certain neurological diseases. The nanomaterial-autophagy interaction therefore must be treated with caution for therapeutic molecules and peptides that require vectorization for their administration.
引用
收藏
页码:166 / 174
页数:9
相关论文
共 104 条
[11]  
[Anonymous], 2012, ANGEW CHEM, V124, P6495
[12]   Autophagy-regulating small molecules and their therapeutic applications [J].
Baek, Kyung-Hwa ;
Park, Jihye ;
Shin, Injae .
CHEMICAL SOCIETY REVIEWS, 2012, 41 (08) :3245-3263
[13]   Carbon nanomaterials as new tools for immunotherapeutic applications [J].
Battigelli, Alessia ;
Menard-Moyon, Cecilia ;
Bianco, Alberto .
JOURNAL OF MATERIALS CHEMISTRY B, 2014, 2 (37) :6144-6156
[14]   The DWEYS peptide in systemic lupus erythematosus [J].
Bosch, Xavier ;
Ramos-Casals, Manuel ;
Khamashta, Munther A. .
TRENDS IN MOLECULAR MEDICINE, 2012, 18 (04) :215-223
[15]   Belimumab: Review of Use in Systemic Lupus Erythematosus [J].
Boyce, Eric G. ;
Fusco, Bryan E. .
CLINICAL THERAPEUTICS, 2012, 34 (05) :1006-1022
[16]  
Briand J.-P., 2005, AUTOANTIBODIES AUTOI, P189
[17]  
Briand JP, 2014, METHODS MOL BIOL, V1134, P173, DOI 10.1007/978-1-4939-0326-9_13
[18]   Emerging Peptide Therapeutics for Inflammatory Autoimmune Diseases [J].
Briand, Jean-Paul ;
Muller, Sylviane .
CURRENT PHARMACEUTICAL DESIGN, 2010, 16 (09) :1136-1142
[19]   APPLICATION AND LIMITATIONS OF THE MULTIPLE ANTIGEN PEPTIDE (MAP) SYSTEM IN THE PRODUCTION AND EVALUATION OF ANTIPEPTIDE AND ANTIPROTEIN ANTIBODIES [J].
BRIAND, JP ;
BARIN, C ;
VANREGENMORTEL, MHV ;
MULLER, S .
JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 156 (02) :255-265
[20]   MULTIPLE AUTOEPITOPE PRESENTATION FOR SPECIFIC DETECTION OF ANTIBODIES IN PRIMARY BILIARY-CIRRHOSIS [J].
BRIAND, JP ;
ANDRE, C ;
TUAILLON, N ;
HERVE, L ;
NEIMARK, J ;
MULLER, S .
HEPATOLOGY, 1992, 16 (06) :1395-1403